{"schema_version":"secwatch.filing_event.v1","accession":"0001517022-25-000030","form_type":"8-K","ticker":"AKBA","cik":"0001517022","company_name":"Akebia Therapeutics, Inc.","filed_at":"2025-06-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.570908+00:00","generated_at":"2026-05-19T08:07:19.153375+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Akebia shareholders approve 18.9M share increase to 2023 Stock Incentive Plan","bullets":["Shareholders approved amendment to 2023 Stock Incentive Plan to increase shares by 18,900,000 (102.75M for, 48.21M against).","Directors John P. Butler and Myles Wolf re-elected as Class II directors with over 119.9M votes each.","Advisory vote on executive compensation passed with 110.68M for, 39.01M against.","Ratification of Ernst & Young as auditor for 2025 passed with 178.59M for, 8.90M against."],"urls":{"canonical":"https://secwatch.observer/filing/0001517022-25-000030","json":"https://secwatch.observer/filing/0001517022-25-000030.json","markdown":"https://secwatch.observer/filing/0001517022-25-000030.md","text":"https://secwatch.observer/filing/0001517022-25-000030.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1517022/000151702225000030/0001517022-25-000030-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1517022/000151702225000030/akba-20250610.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T08:07:19.153375+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}